Back to Previous Page
Binh Dinh Pharmaceutical and Medical Equipment (DBD VN) – FY 2025 – Stable Profit Amid Margin Pressure
Summary of FY 2025 results and outlook of Binh Dinh Pharmaceutical and Medical Equipment JSC (DBD VN)
- Net revenue rose 8.0% y/y to VND1,865bn, growth continued to be driven by key specialized treatment segments, including oncology (+12.3% y/y), kidney dialysis (+27.6% y/y), and antibiotics (+4.0% y/y), which together contributed approximately 63.4% of total revenue. By distribution channel, hospital sales recorded stronger growth of 9.6% y/y, reflecting the company’s ongoing strategy to focus on specialized treatment drugs, alongside a gradual expansion into recovery-supporting therapies. Retail sales through pharmacies grew more modestly at 4.2% y/y, as stricter tax and reporting requirements, together with tighter enforcement against counterfeit drugs, continued to weigh on traditional pharmacy channels. Net profit grew 5.7% y/y to VND291bn. Gross profit margin declined to 47.3% (-92 bps y/y), mainly reflecting the reclassification of certain production-related employee costs. Despite a sizable increase in provision for the Science and Technology Development Fund, the operating profit margin remained stable at 17.4%, supported by disciplined operating cost control.
- Pharmaceutical demand continues to benefit from long-term structural driver. As demographic ageing progresses in Vietnam, the population aged over 60 reached 14.5% in 2025 and is projected to exceed 25.0% by 2050, supporting sustained growth in healthcare demand. Alongside rising household incomes, healthcare spending continued to increase, supported by broader access to medical services and higher treatment standards. In parallel, lifestyle-related illnesses are becoming more prevalent among younger populations, driven by imbalanced diets, sedentary habits and environmental factors. At the same time, improvements in healthcare system capabilities enable earlier diagnosis and more consistent treatment, supporting structurally higher medicine consumption, particularly for chronic and serious conditions.
- Favorable regulatory direction further expands the demand base. Recent Ministry of Health (MoH) regulations have broadened National Health Insurance (NHI) reimbursement to lower-tier healthcare facilities, reducing out-of-pocket costs and broadening treatment access nationwide. Furthermore, the MoH is continuously working toward expanding the NHI reimbursement list, alongside increases in the spending budget, with the latest draft indicating a strong focus on targeted oncology treatments.
- 2026 Outlook: The local pharmaceutical market is expected to grow at an 8.5% CAGR through 2029, supported by rising demand for chronic disease and specialized treatments, expanded health insurance coverage, and higher household incomes alongside improving healthcare awareness. As a leading domestic producer of specialized drugs, DBD is well positioned to benefit from these trends.
Interested in DBD? Click here to read more of our previous analysis on DBD’s quarterly earnings.
Company ratings and target prices are accessible for clients only.
If you are interested in getting full access to our paid Primary Research Materials feel free to get in touch with us at your convenience.
Our team is actively covering 50 companies in the listed Vietnamese equity space for our clients.
Photo image credit: Bidiphar
